Hilleman Laboratories I f I had to name a person who has done more - PowerPoint PPT Presentation

Hilleman Laboratories

“ I f I had to name a person who has done more for the benefit of human health, with less recognition than anyone else, it would be Maurice Hilleman. Maurice should be recognized as the most successful vaccinologist in history. ” -ROBERT GALLO, Co - discoverer of HIV virus

OUR MISSION Creating new vaccines in areas of unmet need as well as adapting existing vaccines for more effective delivery in low-income nations 3

ORGANIZATIONAL STRUCTURE Strategic Board Of Hilleman Advisory Management Directors Group 4

Merck & Wellcome Trust Joint-Venture WELLCOME TRUST, UK MSD (Merck) - Famous for its contribution to A renowned global Biomedical Research vaccine development corporation. Dr. Gerd Zettlmeissl Dr. Julie Gerberding Chairman Director (Merck) Mr. Sanat Chattopadhyay Prof. Gagandeep Kang MSD – Wellcome Trust, Director (Wellcome Trust) Director (Merck) Hilleman Laboratories Independent Organization Stephen Caddick, PhD Mr. Michael T Nally Director (Wellcome Trust) Director (Merck) 5

Current Projects Optimized Cholera ETEC Vaccine Heat Stable Rotavirus Vaccine Vaccine ฀ Hilleman Laboratories in ฀ Hilleman Laboratories has ฀ Our ETEC vaccine project collaboration with Gotovax AB (a involves generation of genetically begun to work on the University of Gothenburg spin-off modified vaccine strains that development of a thermostable biopharmaceutical company) contain highly expressed oral rotavirus vaccine to allow for aims to deliver a high impact Oral immunogenic antigens selected greater temperature consistency Cholera vaccine at a significantly using in-silico reverse vaccinology and less reliance on exact storage more affordable price than the approaches together with timing and refrigeration . ones currently available in the publically available whole market. genome sequence data. 6

Current Projects (CONT.) Shigella Vaccine Low-cost Meningococcal Conjugate Vaccine Hilleman Labs uses a two-pronged strategy to Our Shigella vaccine is a collaboration with develop low-cost vaccine for prevention of invasive National Institute of Cholera and Enteric meningococcal disease - conventional methods to Diseases, Kolkata (NICED) and the Indian develop conjugate vaccines covering A,C,Y,W & X Council of Medical Research (ICMR). Hilleman serogroups, and a novel method using synthetic Labs and NICED will develop vaccines against organic chemistry to create short oligosaccharides. the infection and establish proof-of-concept Our method has the potential to significantly reduce in the clinic. Our partner, ICMR, brings a costs and create new IP, allowing developing country wealth of expertise in clinical research and manufacturers undertake more conjugate vaccine development of vaccines. Together, we will development projects. accelerate development of our novel Shigella vaccine. 7

OUR MODEL FOR SUCCESS MFG & Innovative Income R & D Ideas Sales Sustainability Innovative Ideas R & D Manufacturing & Sales Funding for our business Innovations are Our vision as a non-profit Ideas are pre-selected model is primarily obtained company allows us to build based upon global impact, converted into through Innovative powerful vaccines partnerships with vaccine feasibility of the problem, Financing and Product manufacturers who through the process of competitive landscape for Sales. To date our focus assemble our products and development purposes. translational has been on vaccines and Research and sell them. infectious diseases. Development. 8

Hilleman Lab ’ s Unique Approach What makes Hilleman Laboratories different? ฀ Hilleman Laboratories has designed vaccines which directly meets the needs of the developing world. ฀ These vaccines can be orally administered, are affordable for poor communities, and are also heat-stable up to 45 ° C. 9

Progression 2012 2015 2016 Early 2014 Late 2014 Present Preclinical success of Rotavirus and Cholera Hilleman Labs announces MSD & Wellcome Trust Announced collaboration with Hilleman Labs signs MoU with Meningococcal & HiB vaccines Vaccines proceed into Stage collaboration with Kolkata open R&D facility in Jamia Gotovax AB-Sweden in order Bangladesh based icddr-b in indicates predictive results. II of clinical trials. Novel based NICED to develop and Hamdard University, to develop a high impact order to fast track clinical New vaccines are cost ETEC vaccine initiated commercialize a vaccine New Delhi, INDIA Cholera vaccine. trials effective & meet needs of against Shigella. developing countries. 10

Sustainability ฀ Hilleman Laboratories develops its vaccines through grants and project based funding. ฀ Vaccine Research & Development, is making substantial progress through partnerships, and sustainable development. 11

Vision To be recognized as the Forge Relationships Continue development of Center of Excellence for strengthening public vaccines for various early-stage private partnerships in diseases affecting development of vaccines order to manufacture developing countries. by bringing together the and commercialize Initiate registration stage scientific prowess of vaccines at affordable for Rotavirus & Cholera global partners and cost. vaccines. funders to benefit the world ’ s poorest. 12

Our Partners OUR OFFICE 13

CONNECT 14

THANK YOU 15